Fast and Robust LC-UV-MS Based Peptide Mapping Using RapiZyme™ Trypsin and IonHance™ DFA

Importance of the Topic

Peptide mapping is a cornerstone technique in proteomics and biopharmaceutical analysis for confirming protein identity, determining primary structure, and detecting post-translational modifications. Robust and efficient workflows are critical for quality control and R&D applications, where rapid turnaround and reproducibility can directly impact decision making in drug development and manufacturing environments.

Aims and Study Overview

This work presents a fast, robust liquid chromatography–UV–mass spectrometry (LC-UV-MS) peptide mapping protocol using RapiZyme™ Trypsin and IonHance™ difluoroacetic acid (DFA). Key objectives:

• Reduce digestion time from ≥3 hours to ~1 hour through high-activity, autolysis-resistant trypsin.
• Eliminate mobile phase adducts while optimizing simultaneous UV and MS detection.
• Demonstrate method performance using MassPREP peptide standards and the NISTmAb biotherapeutic standard.

Used Instrumentation

• LC system: ACQUITY UPLC I-Class PLUS
• UV detection: ACQUITY TUV/PDA detector at 219 nm
• Column: ACQUITY Premier Peptide CSH C18, 1.7 µm, 2.1×150 mm, 65 °C
• MS system: ACQUITY RDa with MSe acquisition (50–2000 m/z)
• Software: UNIFI v3.0.0.15 for LC-MS and Empower 3 for UV-only runs

Methodology

• Sample preparation: Denature NISTmAb with 6 M GuHCl, reduce with DTT, alkylate with iodoacetamide, and desalting via SEC cartridge in Tris-CaCl₂ buffer.
• Protein estimation: A280 measurement to ensure a consistent enzyme:protein ratio.
• Digestion: 1:5 (w/w) RapiZyme Trypsin to protein, 37 °C, 300 rpm for 1 hour; quench with formic acid.
• Chromatography: 0.1% (v/v) IonHance DFA in water (A) and 0.07% in acetonitrile (B); flow rate 0.25 mL/min; 50 µL injection; 6 °C autosampler.
• MS parameters: Capillary 1.2 kV, cone 20 V, fragmentation 60–120 V, desolvation 350 °C, positive polarity, 2 Hz scan.

Main Results and Discussion

• Achieved 100% sequence coverage of both heavy and light chains of NISTmAb under 3-hour sample prep.
• No detectable DFA adducts in peptide spectra, preserving high-quality sequence-informative fragment ions.
• Enhanced, sequence-independent UV sensitivity allowed detection of low-abundance peptides previously obscured with formic acid.
• Retention time reproducibility was improved by DFA ion pairing, as shown by overlayed UV and base peak intensity chromatograms across triplicate digests.

Benefits and Practical Applications

• Reduced digestion time and overall prep under 3 hours accelerates protein characterization workflows.
• Adduct-free, high-sensitivity UV and MS data support reliable identification and quantitation.
• Initial LC-UV-MS peptide annotation allows routine UV-only runs for QC, reducing instrument time and cost.
• Reproducible retention and signal intensity facilitate transfer to regulated biopharmaceutical QC environments.

Future Trends and Potential Applications

• Integration into automated, high-throughput platforms for large-scale proteomic studies.
• Extension to other proteases and complex protein classes to broaden method applicability.
• Further optimization of ion-pairing additives for enhanced chromatographic performance across diverse analytes.
• Adoption as a platform method in regulated biopharma QC for release testing and stability studies.

Conclusion

The combination of RapiZyme™ Trypsin and IonHance™ DFA delivers a fast, robust, and reproducible peptide mapping platform. By reducing digestion times, eliminating adducts, and enhancing UV and MS sensitivity, this workflow addresses critical needs in protein characterization and biopharmaceutical quality control.

References

1. Nguyen JM, Smith J, Rzewuski S, Legido-Quigley C, Lauber MA. High Sensitivity LC-MS Profiling of Antibody-Drug Conjugates With Difluoroacetic Acid Ion Pairing. MAbs. 2019;11(8):1358–1366. doi:10.1080/19420862.2019.1658492.
2. Gross ML, Chen G, Pramanik BN. Protein and Peptide Mass Spectrometry in Drug Discovery. 2012.
3. Mouchahoir T, Schiel JE. Development of an LC-MS/MS Peptide Mapping Protocol for the NISTmAb. Anal Bioanal Chem. 2018;410(8):2111–2126. doi:10.1007/s00216-018-0848-6.